NeuroSense CMO to step down, remain as advisor

NeuroSense Therapeutics Ltd. reported a leadership change in its medical team.

Rhea-AI Filing Summary

NeuroSense Therapeutics Ltd. reported a leadership change in its medical team. Dr. Ferenc Tracik will step down as Chief Medical Officer effective April 27, 2026, but will remain involved with the company as an independent advisor.

The company states that his departure does not arise from any disagreement on operations, policies, or practices. In his advisory role, Dr. Tracik will continue to support clinical development and provide strategic medical guidance for the PrimeC program, including around an upcoming Pre-NDS meeting with Health Canada.

Key Figures

CMO transition effective date: April 27, 2026 Announcement date: April 24, 2026

2 metrics

CMO transition effective date April 27, 2026 Date Dr. Ferenc Tracik steps down as Chief Medical Officer

Announcement date April 24, 2026 Date NeuroSense reported the CMO transition

Key Terms

Report of Foreign Private Issuer, Pre-NDS meeting, PrimeC program, independent advisor, +1 more

5 terms

Report of Foreign Private Issuer regulatory

"FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16"

A report of a foreign private issuer is a formal filing that a non‑U.S. company makes to U.S. regulators to share important business, financial, or governance information with American investors. Think of it as a regular update or press packet that keeps investors informed about events that could change a company’s value—like earnings, management changes, contracts, or regulatory developments—so investors can make timely, informed decisions.

Pre-NDS meeting regulatory

"including in connection with the upcoming Pre-NDS meeting with Health Canada"

PrimeC program financial

"provide strategic medical guidance on the Company’s PrimeC program"

independent advisor financial

"Dr. Tracik will continue to support the Company as an independent advisor"

Health Canada regulatory

"including in connection with the upcoming Pre-NDS meeting with Health Canada"

Health Canada is the government department responsible for overseeing the safety and regulation of health-related products and services in Canada, including medications, medical devices, and vaccines. Its approval and guidelines help ensure that these products are safe and effective for public use. For investors, Health Canada's decisions can influence the success of healthcare companies and affect the availability of new medical treatments in the Canadian market.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What leadership change did NeuroSense Therapeutics (NRSN) announce in April 2026?

NeuroSense Therapeutics announced that Dr. Ferenc Tracik will step down as Chief Medical Officer effective April 27, 2026. He will continue working with the company as an independent advisor, focusing on clinical development and strategic medical guidance for the PrimeC program.

When does NeuroSense Therapeutics’ CMO transition become effective?

The transition becomes effective on April 27, 2026, when Dr. Ferenc Tracik steps down as Chief Medical Officer. After that date, he will remain engaged with NeuroSense as an independent advisor supporting ongoing clinical development and strategy for the PrimeC program.

Did Dr. Ferenc Tracik leave NeuroSense Therapeutics (NRSN) due to a disagreement?

No. NeuroSense states that Dr. Tracik’s departure as Chief Medical Officer is not due to any disagreement regarding the company’s operations, policies, or practices. He will continue collaborating with the company in an advisory capacity on clinical and strategic matters.

What role will Dr. Tracik have at NeuroSense Therapeutics after stepping down as CMO?

After stepping down as Chief Medical Officer, Dr. Tracik will serve as an independent advisor. He will support ongoing clinical development activities and provide strategic medical guidance on NeuroSense’s PrimeC program, including involvement in the upcoming Pre-NDS meeting with Health Canada.

How is Dr. Tracik involved in NeuroSense Therapeutics’ PrimeC program?

Dr. Tracik will offer strategic medical guidance for the PrimeC program in his new advisory role. His responsibilities include contributing to ongoing clinical development and supporting preparations for an upcoming Pre-NDS meeting with Health Canada related to the program’s advancement.

What regulatory interaction related to PrimeC does NeuroSense Therapeutics mention?

NeuroSense cites an upcoming Pre-NDS meeting with Health Canada related to its PrimeC program. In his advisory role, Dr. Tracik will help provide strategic medical guidance and support clinical development activities connected to this planned regulatory interaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/24/2026 - 09:20 AM EDT Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the Month of April 2026

Commission File Number: 001-41084

NeuroSense Therapeutics Ltd.
(Translation of registrant’s name into English)

NeuroSense Therapeutics Ltd.

11 HaMenofim Street, Building B
Herzliya 4672562 Israel
+972-9-7996183
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Explanatory Note

On April 24, 2026, NeuroSense Therapeutics Ltd. (the “Company”) announced that Dr. Ferenc Tracik, M.D., will step down from his role as Chief Medical Officer, effective April 27, 2026. Dr. Tracik will continue to support the Company as an independent advisor.

Dr. Tracik’s departure is not the result of any disagreement with the Company on matters relating to its operations, policies, or practices.

In his advisory capacity, Dr. Tracik will contribute to ongoing clinical development activities and provide strategic medical guidance on the Company’s PrimeC program, including in connection with the upcoming Pre-NDS meeting with Health Canada.

The Company thanks Dr. Tracik for his leadership and contributions and looks forward to continuing to benefit from his expertise. 

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	NeuroSense Therapeutics Ltd.
Date: April 24, 2026	By:	/s/ Alon Ben-Noon
		Alon Ben-Noon
		Chief Executive Officer

2